developed a CRISPR/Cas9‐LNP system to selectively knockout SOX2 in HNSCC cells.[51] This genome‐editing strategy effectively inhibited tumor cell growth in vitro and demonstrated significant therapeutic efficacy in tumor‐bearing mice following intratumoral injection, leading to a 90% increase in survival (>84 days). This evidence concerns the gene SOX2 and neoplasm.